CN107922437B - 桥连哌啶衍生物 - Google Patents

桥连哌啶衍生物 Download PDF

Info

Publication number
CN107922437B
CN107922437B CN201680051165.9A CN201680051165A CN107922437B CN 107922437 B CN107922437 B CN 107922437B CN 201680051165 A CN201680051165 A CN 201680051165A CN 107922437 B CN107922437 B CN 107922437B
Authority
CN
China
Prior art keywords
triazolo
endo
pyridin
azabicyclo
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680051165.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN107922437A (zh
Inventor
卡尔海因茨·博伊曼
吉多·加利
罗兰·雅各布-勒特
安雅·林贝格
维尔纳·奈德哈特
罗莎·马丽亚·罗得里格斯萨尔米恩托
比约恩·巴特尔斯
哈萨内·拉特尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN107922437A publication Critical patent/CN107922437A/zh
Application granted granted Critical
Publication of CN107922437B publication Critical patent/CN107922437B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201680051165.9A 2015-09-09 2016-09-05 桥连哌啶衍生物 Active CN107922437B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15184480 2015-09-09
EP15184480.0 2015-09-09
PCT/EP2016/070800 WO2017042114A1 (en) 2015-09-09 2016-09-05 Bridged piperidine derivatives

Publications (2)

Publication Number Publication Date
CN107922437A CN107922437A (zh) 2018-04-17
CN107922437B true CN107922437B (zh) 2021-12-10

Family

ID=54072754

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680051165.9A Active CN107922437B (zh) 2015-09-09 2016-09-05 桥连哌啶衍生物

Country Status (7)

Country Link
US (1) US10604517B2 (https=)
EP (1) EP3347363B1 (https=)
JP (1) JP6831372B2 (https=)
CN (1) CN107922437B (https=)
AR (1) AR105965A1 (https=)
TW (1) TWI716446B (https=)
WO (1) WO2017042114A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017042114A1 (en) 2015-09-09 2017-03-16 F. Hoffmann-La Roche Ag Bridged piperidine derivatives
JP7012715B2 (ja) * 2016-06-27 2022-01-28 エフ．ホフマン－ラ ロシュ アーゲー γ－セクレターゼモジュレーターとしてのトリアゾロピリジン
WO2018046428A1 (en) * 2016-09-09 2018-03-15 F. Hoffmann-La Roche Ag Process for preparation of 2-(6-nitropyridin-3-yl)-9h-dipyrido[2,3-b;3',4'-d]pyrrole
AR109829A1 (es) * 2016-09-29 2019-01-30 Hoffmann La Roche Derivados de piperidina puenteados
EP3523304B1 (en) 2016-10-04 2021-01-27 H. Hoffnabb-La Roche Ag Bicyclic heteroaryl derivatives
WO2018083050A1 (en) * 2016-11-01 2018-05-11 F. Hoffmann-La Roche Ag Bicyclic heteroaryl derivatives
WO2019121434A1 (en) * 2017-12-18 2019-06-27 F. Hoffmann-La Roche Ag Triazolo-azepine derivatives
CN111417636B (zh) * 2018-01-22 2023-09-26 豪夫迈·罗氏有限公司 三唑并-氮杂䓬衍生物
DK3846903T3 (da) * 2018-09-03 2024-01-02 Hoffmann La Roche Bicykliske heteroarylderivater
CN117946116A (zh) * 2018-12-13 2024-04-30 豪夫迈·罗氏有限公司 6,7-二氢-5h-吡咯并[1,2-b][1,2,4]三唑-2-胺衍生物
ES2940185T3 (es) 2018-12-27 2023-05-04 Hoffmann La Roche Procedimiento para la preparación de exo-N-(3-azabiciclo[3.2.1]octan-8-il)carbamato de terc-butilo
NZ780966A (en) 2019-04-18 2026-02-27 Univ Johns Hopkins Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003211993A1 (en) * 2002-02-15 2003-09-04 Kyowa Hakko Kogyo Co., Ltd. (1,2,4)TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVES
MX2010008700A (es) * 2008-02-22 2010-08-30 Hoffmann La Roche Moduladores de beta-amiloide.
WO2009128669A2 (ko) * 2008-04-16 2009-10-22 엘지이노텍주식회사 발광 소자 및 그 제조방법
CN102209537A (zh) * 2008-11-10 2011-10-05 弗·哈夫曼-拉罗切有限公司 杂环γ分泌酶调节剂
TWI461425B (zh) * 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
AU2010262036B2 (en) * 2009-05-07 2014-10-30 Cellzome Limited Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators
WO2010138901A1 (en) * 2009-05-29 2010-12-02 Biogen Idec Ma Inc Carboxylic acid-containing compounds, derivatives thereof, and related methods of use
US20110117966A1 (en) * 2009-10-23 2011-05-19 Appsware Wireless, Llc System and Device for Consolidating SIM, Personal Token, and Associated Applications
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
US8486967B2 (en) * 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
EP2687528A1 (en) * 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
WO2017042114A1 (en) 2015-09-09 2017-03-16 F. Hoffmann-La Roche Ag Bridged piperidine derivatives

Also Published As

Publication number Publication date
CN107922437A (zh) 2018-04-17
JP2018526410A (ja) 2018-09-13
US20180237432A1 (en) 2018-08-23
US10604517B2 (en) 2020-03-31
TW201718601A (zh) 2017-06-01
EP3347363A1 (en) 2018-07-18
HK1251902A1 (zh) 2019-04-26
TWI716446B (zh) 2021-01-21
EP3347363B1 (en) 2020-01-01
WO2017042114A1 (en) 2017-03-16
AR105965A1 (es) 2017-11-29
JP6831372B2 (ja) 2021-02-17

Similar Documents

Publication Publication Date Title
CN107922437B (zh) 桥连哌啶衍生物
TWI855062B (zh) Bcl-2抑制劑
JP6977111B2 (ja) Ｉｒａｋ４阻害剤としての二環式ヘテロシクリル誘導体
CN108137579B (zh) 桥连哌啶衍生物
CN110248939B (zh) 作为rho-激酶抑制剂的酪氨酸酰胺衍生物
EP2655357B1 (en) Indazolyl triazole derivatives as irak inhibitors
CN114867727A (zh) Tau蛋白靶向化合物及相关使用方法
TWI757360B (zh) 苯氧基三唑
TW201443023A (zh) 作爲ｒｏｃｋ抑制劑之酞□酮及異喹啉酮
EP3092226A1 (en) Indazole compounds as irak4 inhibitors
CN110520423A (zh) 作为激酶抑制剂的氨基三唑并吡啶
KR20100055456A (ko) 다환식 화합물
HK1254348A1 (zh) 毒蕈碱性m2受体的正性变构调节剂
WO2024114787A1 (zh) 酰胺或脲类化合物
US20210380578A1 (en) Multicyclic compounds as farnesoid x receptor modulators
CN109071548A (zh) 可用于治疗尤其是癌症的吡咯并咪唑衍生物或其类似物
CN115429798A (zh) 7-取代的1-芳基二氮杂萘-3-羧酰胺及其用途
WO2010059611A2 (en) Inhibitors of diacylglycerol acyltransferase
WO2020116662A1 (ja) シクロアルカン−１，３−ジアミン誘導体
HK1251902B (zh) 桥连哌啶衍生物
TWI919070B (zh) 醯胺雜芳香族化合物及其用途
CN101039947A (zh) Hcv复制抑制剂
HK1254787A1 (en) Bridged piperidine derivatives
HK40083699B (zh) 具有kdm5抑制活性的3-氮杂二环(3.1.0)己烷衍生物及其用途
HK1254787B (zh) 桥连哌啶衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1251902

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant